Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;21(8):536-552.
doi: 10.1038/s41581-025-00963-0. Epub 2025 Apr 25.

Drivers and mechanisms of cognitive decline in chronic kidney disease

Affiliations
Review

Drivers and mechanisms of cognitive decline in chronic kidney disease

Giovambattista Capasso et al. Nat Rev Nephrol. 2025 Aug.

Abstract

Cognitive impairment is highly prevalent among individuals with chronic kidney disease (CKD). Despite its high prevalence, the contributing factors and mechanisms underlying brain-kidney dysfunction in CKD remain poorly understood. However, advances in neuroscience, including novel imaging techniques and cognitive assessment methods, have begun to clarify this complex relationship. Several factors contribute directly to cognitive decline in people with CKD, including accumulation of uraemic toxins, microvascular damage, malnutrition, chronic inflammation and disruptions in key neuroprotective pathways, such as those involving Klotho and the glymphatic system. These factors are also linked to the accelerated ageing observed in people with CKD, a key contributor to cognitive decline. However, most studies on cognition in people with CKD have been cross-sectional and associative, offering limited insight into causation. Research advances, such as studies on the effect of uraemic toxins on the blood-brain barrier and the role of the endothelial glycocalyx in vascular damage, offer promising new directions. Emerging data from longitudinal cohort studies are also enhancing our understanding of these processes, with potential implications for both the treatment of CKD-related cognitive decline and the broader issue of cognitive dysfunction in ageing populations. Here, we examine key mechanisms linking CKD to cognitive decline and consider potential therapeutic interventions.

PubMed Disclaimer

Conflict of interest statement

Competing interests: A.O. has received grants from Sanofi, and consultancy or speaker fees or travel support from Adviccene, Alexion, Astellas, Astrazeneca, Amicus, Amgen, Bioporto, Boehringer Ingelheim, Esteve, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Sobi, Menarini, Mundipharma, Kyowa Kirin, Lilly, Freeline, Idorsia, Chiesi, Otsuka, Novo-Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma and Spafarma; is the Director of the Catedra UAM-Astrazeneca of chronic kidney disease and electrolytes; and owns Telara Farma stock. C.F.M.F. received research grants from Baxter, Fresenius and Sandoz; and is on the Advisory board of Pharvaris. C.A.W. reports honoraria from Kyowa Kirin and Medice; and scientific collaboration with Bayer AG. M.D.O. is on the scientific advisory board of AstraZeneca. R.I.M. is currently employed as Senior Director Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Z.A.M. reports grants from Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline, Merck Sharp and Dohme-Chibret, Genzyme/Sanofi, Lilly, Otsuka and Boehringer Ingelheim; Government support for CKD REIN PROJECT AND EXPERIMENTAL PROJECTS; and payment or honoraria for lectures and presentations to charities from AstraZeneca, GSK and Boehringer Ingelheim. R.J.U. is currently employed as a Chief Scientist by AstraZeneca Biopharmaceuticals R&D, Translational Science and Experimental Medicine (TSEM), and Early Cardiovascular, Renal and Metabolism (eCVRM), Cambridge, UK. M.N. is a paid consultant for CNS2 for unrelated work. The other authors declare no competing interests.

References

    1. Collaboration, G. B. D. C. K. D. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395, 709–733, doi: 10.1016/S0140-6736(20)30045-3 (2020). - DOI - PMC - PubMed
    1. Viggiano D et al. Mechanisms of cognitive dysfunction in CKD. Nature Review Nephrology 16, 452–469, doi: 10.1038/s41581-020-0266-9 (2020). - DOI - PubMed
    1. de Boer A et al. Consensus-Based Technical Recommendations for Clinical Translation of Renal Phase Contrast MRI. Journal of Magnetic Resonance Imaging 55, 323–335, doi: 10.1002/jmri.27419 (2022). - DOI - PMC - PubMed
    1. Wikoff WR, Nagle MA, Kouznetsova VL, Tsigelny IF & Nigam SK Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res 10, 2842–2851, doi: 10.1021/pr200093w (2011). - DOI - PMC - PubMed
    1. Rosner MH et al. Classification of Uremic Toxins and Their Role in Kidney Failure. Clin J Am Soc Nephrol 16, 1918–1928, doi: 10.2215/CJN.02660221 (2021). - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources